A new study suggests that Eliquis, one of the most widely prescribed blood-thinning medications in Canada, is likely safer for patients with dementia than older alternatives such as warfarin, according to CBC Ottawa.
For Ottawa's growing senior population and the healthcare workers who care for them, the research offers clinically important guidance that could influence prescribing practices across the city.
What the Study Found
Researchers examined outcomes for patients living with both atrial fibrillation (a heart rhythm disorder requiring anticoagulation) and dementia, a combination that presents significant treatment challenges. Patients with dementia face elevated fall risk, which can be catastrophic when combined with blood thinners that make bleeding harder to control.
The study found that patients with dementia who took Eliquis (apixaban) experienced lower rates of serious bleeding complications compared to those on warfarin, while maintaining similar protective effects against stroke. The findings suggest Eliquis offers a better risk-benefit profile for this vulnerable population.
Why This Matters in Ottawa
Ottawa is home to world-class healthcare institutions, the Ottawa Hospital, CHEO, Bruyère Continuing Care, and the Queensway Carleton Hospital, collectively caring for thousands of patients with dementia and related conditions each year.
For Ottawa physicians, cardiologists, and geriatric specialists, guidance on safer medication options for cognitively impaired patients is clinically significant. It may prompt reconsideration of prescribing patterns in hospital and long-term care settings across the National Capital Region.
Context: Eliquis in Canada
Eliquis belongs to a newer class of oral anticoagulants (NOACs) that have largely replaced warfarin in many patient populations due to more predictable dosing and fewer dietary interactions. However, NOAC medications are significantly more expensive than warfarin, raising access questions for seniors on fixed incomes.
Ontario's drug plan (ODB) covers Eliquis for eligible patients, though coverage rules vary. Families and caregivers should speak with a physician to understand what's covered.
What Patients and Caregivers Should Do
Anyone caring for an Ottawa family member with dementia who is also on anticoagulation therapy should raise this study with their physician. Don't stop or change any medication without professional advice. This research adds to the evidence base but does not replace individualized medical guidance.
Ottawa's senior-care network, including the Champlain LHIN, Ottawa Community Support and family health teams, can help connect caregivers with appropriate medical resources.
Source: CBC Ottawa
